<DOC>
	<DOCNO>NCT00854308</DOCNO>
	<brief_summary>This Phase II , double-blind , randomize , multicenter trial design preliminarily evaluate activity safety treatment MetMAb + erlotinib versus erlotinib + placebo second- third-line Non-Small Cell Lung Cancer ( NSCLC ) . Up 180 patient randomize 1:1 ratio one two treatment arm .</brief_summary>
	<brief_title>A Study MetMAb Administered Patients With Advanced Non-Small Cell Lung Cancer , Combination With Tarceva ( Erlotinib )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients must meet follow criterion study entry : Histologically confirm NSCLC Availability tumor specimen Recurrent progressive disease follow least one chemo contain regimen Stage IIIB/IV disease Measurable disease accordance Response Evaluation Criteria Solid Tumors ( RECIST ) At least one measurable lesion pretreatment 18fluorodeoxyglcoseâˆ’positron emission tomography ( FDGPET ) scan also target lesion compute tomography ( CT ) accord RECIST More two prior treatment Stage IIIB/IV More 30 day exposure investigational market agent act EGFR inhibition , know epidermal growth factor receptor ( EGFR ) relate toxicity result dose modification Chemotherapy , biologic therapy , radiotherapy investigational drug within 28 day prior randomization Untreated and/or active ( progress require anticonvulsant corticosteroid symptomatic control ) central nervous system ( CNS ) metastasis History serious systemic disease within past 6 month prior randomization Uncontrolled diabetes Major surgical procedure significant traumatic injury within 28 day prior randomization Anticipation need major surgical procedure course study Local palliative radiotherapy within 7 day prior randomization persistent adverse effect radiotherapy resolve Grade II less prior randomization Symptomatic hypercalcemia require continue use bisphosphonate therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Tarceva</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>NSCLC</keyword>
</DOC>